PDCD1 and neoplasm: Besides, a meta-analysis of 8730 patients with various tumor types reported a similar trend, with a reduced risk of any-grade and grade ≥ 3 IRAEs associated with PD-L1 inhibitors compared to PD-1 inhibitors [11].